Screening to Improve Survival in AL Amyloidosis
Sponsor: |
NIH |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT5401 |
U.S. Govt. ID: |
NCT04615572 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this research study is to see whether the presence or absence of certain genes is associated with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS). Each person's disease has different genetic markers that make their disease behave in unique ways. In AL amyloidosis, several common genes have been identified across subject populations. We believe that these common germline genes may be linked to the early development of the disease. By screening subjects with early-stage blood disorders (SMM and MGUS), we will determine if the specific germline genes are present in each participant and whether the genes are associated with the development of systemic (whole-body) AL amyloidosis. We hope this study will help us begin to understand whether this type of germline gene testing is a useful tool for assessing a subject's risk of progressing to AL amyloidosis.
This study is closed
Investigator
Suzanne Lentzsch, MD
Are you age 60 or older? |
Yes |
No |
Have you been diagnosed with SMM or MGUS? |
Yes |
No |